Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin)

This publication has 73 references indexed in Scilit:

• Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
  The Journal of Clinical Pharmacology, 1996
• A phase I clinical evaluation of liposome-entrapped doxorubicin (Lip-Dox) in patients with primary and metastatic hepatic malignancy
  Anti-Cancer Drugs, 1992
• A Health Status Questionnaire Using 30 Items From The Medical Outcomes Study
  Medical Care, 1991
• Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study
  European Journal of Cancer and Clinical Oncology, 1989
• Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacy
  European Journal of Cancer and Clinical Oncology, 1989
• Clinical Pharmacokinetics of Doxorubicin
  Clinical Pharmacokinetics, 1988
• Characterization, toxicity and therapeutic efficacy of adrïamycin encapsulated in liposomes
  European Journal of Cancer and Clinical Oncology, 1982
• The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation
  FEBS Letters, 1980
• Techniques for right and left ventricular endomyocardial biopsy
  The American Journal of Cardiology, 1978
• The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs
  Biochemical and Biophysical Research Communications, 1975